Recently, our company achieved a significant breakthrough in the medical device field, simultaneously obtaining approvals for elastic fiber staining solution, melanin staining solution (ferrous sulfate method), acetic acid chloride AS-D naphthol esterase (AS-DNCE) staining solution, Oil Red O staining solution, eosin staining solution, Wright-Giemsa staining solution, acid-fast staining solution, and calcium salt staining solution (silver nitrate method). This significant achievement marks a new milestone in our company's product portfolio and technical capabilities within in vitro diagnostic reagents, particularly in the field of histochemical staining for pathology. It will provide more comprehensive and precise tool support for clinical pathological diagnosis.

Detailed Explanation of Approved Product Uses and Clinical Significance

All eight approved products fall under histochemical staining solutions within in vitro diagnostic reagents. They are primarily used for staining pathological tissue sections, assisting clinicians in observing cellular morphology and specific components under microscopy. This provides critical evidence for disease diagnosis, classification, and treatment evaluation:

Elastic Fiber Staining Solution

Primary Use: Specifically demonstrates elastic fibers within tissues.

Clinical Significance: Widely used in diagnosing cardiovascular diseases (e.g., atherosclerosis, hypertensive vascular lesions), respiratory diseases (e.g., emphysema), and cutaneous elastofibromas, aiding in assessing damage and repair of tissue elastic structures.

Melanin Stain Solution (Ferrous Sulfate Method)

Primary Use: Detection of melanin granules in tissues.

Clinical Significance: Used for differential diagnosis of skin tumors like melanoma and pigmented nevi, assisting in determining tumor nature and cellular origin.

Chloracetic Acid AS-D Naphthol Esters (AS-DNCE) Stain

Primary Use: Specific labeling of enzyme activity in granulocytes and their precursor cells.

Clinical Significance: Critical in hematologic disease diagnosis, commonly used for differential classification of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Oil Red O Stain Solution

Primary Use: Visualizes neutral fats and lipids within tissues.

Clinical Significance: Used in diagnosing fatty liver disease, atherosclerotic plaques, and steatosis, providing direct visualization of lipid deposition levels.

Eosin Stain Solution

Primary Use: Used in combination with hematoxylin (HE staining) for contrast staining of cytoplasm, collagen fibers, and other components.

Clinical Significance: Serves as the foundational staining for routine histopathology, providing essential color contrast for morphological observation. It constitutes the first step in the majority of pathological diagnoses.

Giemsa Stain Solution

Primary Use: Used for staining cells in blood smears, bone marrow smears, and bodily fluid samples.

Clinical Significance: Widely applied in hematological diagnosis, parasitological examination (e.g., malaria), and cellular morphology analysis, serving as a core staining method in hematology laboratories.

Acid-Fast Staining Solution

Primary Use: Specifically stains acid-fast bacilli.

Clinical Significance: A critical technique for tuberculosis diagnosis, used to detect Mycobacterium tuberculosis in sputum and tissue samples, playing a vital role in infectious disease prevention and control.

Calcium Salt Stain (Silver Nitrate Method)

Primary Use: Visualizes calcium salt deposits in tissues.

Clinical Significance: Aids diagnosis of metastatic calcification, dystrophic calcification, and related lesions (e.g., mammary calcification, arterial calcification), assisting in identifying tissue metabolic abnormalities.

Advancing Pathological Diagnosis, Serving Precision Medicine

The eight newly approved products cover diverse staining requirements from basic morphology to specific chemical component analysis, collectively forming a comprehensive pathological diagnostic staining solution. This successful registration not only demonstrates our company's compliance in R&D and production quality systems for in vitro diagnostic reagents but also reflects our commitment to addressing unmet clinical needs through technological innovation.

Moving forward, our company will continue to deepen its expertise in the field of pathology diagnostics, accelerating product commercialization and market expansion. This will enable these precise staining reagents to rapidly serve pathology departments in major hospitals nationwide, independent laboratories, and research institutions, contributing professional expertise to elevate China's precision medicine capabilities.